The activity of these inhibitors, tested on diverse cancer cell lines, did not give the expected antiproliferative effects or other related phenotypes, despite genetic lockdown of TRIM24 resulting in antiproliferative phenotypes and overexpression of TRIM24 correlated with poor patient prognosis.[58] These findings suggest that TRIMBRD inhibition alone might not be sufficient as an anti‐cancer strategy. The gene discussed is TRIM24; the disease is cancer.